Premium
TScan Therapeutics Inc (TCRX)
NASDAQ
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment... TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. Show more
WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T...
WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T...
To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14) No dose-limiting...
WALTHAM, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered...
WALTHAM, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.11 | 4.34782608696 | 2.53 | 2.67 | 2.39 | 162083 | 2.51894552 | CS |
| 4 | -0.44 | -14.2857142857 | 3.08 | 3.1329 | 2.305 | 290456 | 2.67735987 | CS |
| 12 | -3.25 | -55.1782682513 | 5.89 | 5.92 | 2.305 | 418983 | 3.27726426 | CS |
| 26 | -3.67 | -58.1616481775 | 6.31 | 6.58 | 2.305 | 309416 | 4.18380477 | CS |
| 52 | -2.52 | -48.8372093023 | 5.16 | 9.69 | 2.305 | 295452 | 5.52434948 | CS |
| 156 | -1.98 | -42.8571428571 | 4.62 | 9.69 | 1.45 | 271959 | 4.25104305 | CS |
| 260 | -9.36 | -78 | 12 | 14.71 | 1.45 | 240372 | 4.43771518 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
